Table 2. Papers cited in the review in chronological order.
| Number of cases | Database | Type of cancer | Specific analysis for size | OS | LT vs. TT CSM/DSS | LR | |
|---|---|---|---|---|---|---|---|
| 1988 Grant | 20,600 | Single Institution | PC | No | – | – | In favour of TT Odds ratio >1.0 |
| 1993 Mazzaferri | 1,088 | Single Institution | PC | Yes | For >1.5 cm in favour of TT odds ratio >1.0 | – | In favour of TT Odds ratio >1.0 |
| 1998 Hay | 2,444 | Single Institution | PC | No | – | No difference | – |
| 2002 Hay | 1,685 | Single Institution | PC | No | – | No difference | In favour of TT odds ratio >1.0 |
| 2005 Haigh | 5,432 | SEER | PC | Yes | Subgroups 1–4 cm no difference | – | – |
| 2007 Bilimora | 57,173 | NCDD | PC | Yes | Size >1 cm in favour of TT odds ratio >1.0 | – | In favour of TT odds ratio >1.0 |
| 2010 Barney | 23,605 | SEER | PC | Yes | Subgroups 1–4 cm in favour of TT odds ratio >1.0 | – | – |
| 2010 Ito | 2,638 | Single Institution | PC | Yes | – | – | In favour of TT odds ratio >1.0 |
| 2010 Mendelsohn | 22,724 | SEER | PC | Yes | Subgroups 1–4 cm no difference | – | – |
| 2012 Nixon | 899 | Single Institution | WDTC | Yes | 1–2 vs. 2–4 cm no difference | – | – |
| 2013 Lee | 2,014 | Single Institution | PC | Yes | <1.0 cm no difference | – | <1.0 cm no difference |
| 2014 Adam | 61,775 | NCDB | PC | Yes | 1–2 vs. 2–4 cm no difference | – | – |
| 2014 Ebina | 1,187 | Single Institution | PC | Yes | Not evaluable | Not evaluable | Not evaluable |
| 2014 Matsuzu | 1,088 | Single Institution |
PC | Yes | Not evaluable | Not evaluable | Not evaluable |
| 2018 Choi | 2,345 | Single Institution |
PC | Yes | – | – | No difference |
| 2018 Rajjoub | 33,816 | NCDB | PC-FC | Yes | 1–2 vs. 2–4 cm in favour of TT odds ratio >1.0 for PC | – | – |
| 2019 Liu | 1,087 | Single Institution | PC | No | – | No difference | In favour of TT odds ratio >1.0 |
| 2019 Song | 5,396 | Single Institution | PC-FC | Yes | – | No difference | In favour of TT odds ratio >1.0 |
PC, papillary cancer; WDTC, well differentiated thyroid cancer; OS, overall survival; CSM, cancer specific mortality; DSS, disease specific survival; LR, local recurrence; SEER, Surveillance, Epidemiology, and End Results Program; NCDB, National Cancer Database.